Kronos Bio Q1 2024 Adj EPS $(0.50) Misses $(0.42) Estimate, Sales $2.520M Beat $1.000M Estimate
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio (NASDAQ:KRON) reported Q1 2024 earnings with an adjusted EPS of $(0.50), missing the $(0.42) estimate by 19.05%. However, their sales of $2.520M exceeded the $1.000M estimate by 152%, marking a 106.39% increase from the previous year's $1.221M.
May 09, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Kronos Bio reported a Q1 2024 adjusted EPS of $(0.50), missing estimates, but sales of $2.520M exceeded expectations, showing significant growth.
While the missed EPS could negatively impact investor sentiment towards KRON, the substantial beat on sales estimates and significant year-over-year growth could offset this, leading to a neutral short-term impact on the stock price. The mixed results present both positive and negative signals to investors, making the overall short-term impact uncertain.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100